European experience on the practical use of levosimendan in patients with acute heart failure syndromes

被引：25

作者：

Follath, F

Franco, F

Cardoso, JS

机构：

[1] Univ Zurich Hosp, Dept Internal Med, CH-8091 Zurich, Switzerland

[2] Coimbra Univ Hosp, Coimbra, Portugal

[3] Hosp Sao Joao, Oporto, Portugal

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2005年 / 96卷 / 6A期

关键词：

D O I：

10.1016/j.amjcard.2005.07.025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical effects described in the initial dose-finding and randomized comparative therapeutic trials in patients with severe low-output heart failure. In addition, studies in small series-of patients with cardiogenic shock after myocardial infarction and/or surgical interventions and postinterventional myocardial dysfunction (stunning) indicate that the inotropic and vasodilating actions of,levosimendan may be of value in a wider range of indications. Dose recommendations, combination with other drugs, and potential side effects are discussed in this overview. (c) 2005 Elsevier Inc.

引用

收藏

页码：80G / 85G

页数：6

相关论文

共 32 条

[21] Successful reversal of resistent hypodynamic septic shock with levosimendan [J].

Matejovic, M ;

Krouzecky, A ;

Radej, J ;

Novak, I .

ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2005, 49 (01) :127-127

[22] Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction - A randomized, placebo-controlled, double-blind study (RUSSLAN) [J].

Moiseyev, VS ;

Poder, P ;

Andrejevs, N ;

Ruda, MY ;

Golikov, AP ;

Lazebnik, LB ;

Kobalava, ZD ;

Lehtonen, LA ;

Laine, T ;

Nieminen, MS ;

Lie, KI .

EUROPEAN HEART JOURNAL, 2002, 23 (18) :1422-1432

[23] Hemodynamic effects of Levosimendan added to Dobutamine in patients with decompensated advanced heart failure refractory to Dobutamine alone [J].

Nanas, JN ;

Papazoglou, PP ;

Terrovitis, JV ;

Kanakakis, J ;

Dalianis, A ;

Tsolakis, E ;

Tsagalou, EP ;

Agrios, N ;

Christodoulou, K ;

Anastasiou-Nana, MI .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (10) :1329-1332

[24] Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure [J].

Nieminen, MS ;

Akkila, J ;

Hasenfuss, G ;

Kleber, FX ;

Lehtonen, LA ;

Mitrovic, V ;

Nyquist, O ;

Remme, WJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (06) :1903-1912

[25] Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial [J].

Nijhawan, N ;

Nicolosi, AC ;

Montgomery, MW ;

Aggarwal, A ;

Pagel, PS ;

Warltier, DC .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 34 (02) :219-228

[26] The use of the novel calcium sensitizer levosimendan in critically ill patients [J].

Plöchl, W ;

Rajek, A .

ANAESTHESIA AND INTENSIVE CARE, 2004, 32 (04) :471-475

[27]

Slawsky MT, 2000, CIRCULATION, V102, P2222

[28] The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia [J].

Sonntag, S ;

Sundberg, S ;

Lehtonen, LA ;

Kleber, FX .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2177-2182

[29]

Spargias Konstantinos S, 2003, Ital Heart J, V4 Suppl 2, p45S

[30] Myocardial efficiency during levosimendan infusion in congestive heart failure [J].

Ukkonen, H ;

Saraste, M ;

Akkila, J ;

Knuuti, J ;

Karanko, M ;

Iida, H ;

Lehikoinen, P ;

Någren, K ;

Lehtonen, L ;

Voipio-Pulkki, LM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :522-531

← 1 2 3 4 →